RecruitingPhase 2NCT05998642
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Canadian Cancer Trials Group
- Principal Investigator
- Jean-Francois LaroucheCHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, QC Canada
- Intervention
- Methotrexate(drug)
- Enrollment
- 30 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (8)
- Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- BCCA - Vancouver, Vancouver, British Columbia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
- The Research Institute of the McGill University, Montreal, Quebec, Canada
- CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Quebec, Canada
- Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Collaborators
Janssen Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05998642 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation
- RECRUITINGPHASE1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center
See all trials for Primary central nervous system lymphoma →